| Title: |
Expanding horizons in the treatment of mantle cell lymphoma: Ibrutinib a novel BTK-targeting inhibitor |
| Authors: |
Dhingra, Sameer; Sachdeva, Mamta |
| Source: |
International Journal of Basic & Clinical Pharmacology; Vol. 3 No. 1 (2014): January-February 2014; 249-254 ; 2279-0780 ; 2319-2003 |
| Publisher Information: |
Medip Academy |
| Publication Year: |
2017 |
| Subject Terms: |
Mantle cell lymphoma; BTK-inhibitor; B-cell antigen receptor; Ibrutinib |
| Description: |
Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood, and bone marrow with short remission duration to standard therapies and a median overall survival of 4–5 years. Small molecule inhibitors targeting dysregulated pathways (MAPK/ERK, PI3K/PKB/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders. Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical effectiveness and tolerability in clinical trials, recently been approved by FDA in the treatment of MCL. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://www.ijbcp.com/index.php/ijbcp/article/view/991/894; https://www.ijbcp.com/index.php/ijbcp/article/view/991 |
| Availability: |
https://www.ijbcp.com/index.php/ijbcp/article/view/991 |
| Rights: |
Copyright (c) 2017 International Journal of Basic & Clinical Pharmacology |
| Accession Number: |
edsbas.F7B1FA66 |
| Database: |
BASE |